Investor Relations

Focused on enhancing shareholder value through creating and delivering meaningful advancements in early intervention orthopedic care.
Stock quote is delayed by 15 minutes
NASDAQANIK
Woman throwing punch at punching bag.

Investor Relations

Focused on enhancing shareholder value through creating and delivering meaningful advancements in early intervention orthopedic care.
Stock quote is delayed by 15 minutes
NASDAQANIK
Financial and Operational Metrics

(As of September 30, 2024)

  • $164M

    TTM Revenue

  • $20M

    TTM Adjusted EBITDA

  • $63M

    Cash balance

    with no debt

  • #1

    OA Pain
    U.S. Market Share


    ~25M

    Injections
    Worldwide

Recent News
Oct 31, 2024

BEDFORD, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today reported financial results...

Oct 31, 2024

Company to Focus on Profitable Hyaluronic Acid-Driven OA Pain Management and High Growth Regenerative Solutions Portfolio, Streamline Operations and Enhance Growth Profile BEDFORD, Mass., Oct. 30,...

Oct 17, 2024

BEDFORD, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue...

All Press Releases

Featured Event
Thursday, October 31, 2024
8:30am - 9:30am EDT

See All Events

Current Investor Presentation
Investor Contacts

Primary IR Contact

  • Matt Hall

    Director, Corporate Development and Investor Relations

    Anika Therapeutics, Inc.

    Phone: (781) 457-9554

    Email: investorrelations@anika.com

  • Transfer Agent

    Equiniti Trust Company LLC

    6201 15th Avenue

    Brooklyn NY 11219

    Phone: (800) 937-5449

Want Alerts? Sign up for alerts and never miss an Investor update!

Subscribe

To Top